Inclusion Criteria:~1. Signed an Institutional Review Board (IRB) approved informed consent document indicating
that they understand the purpose of and procedures required by the study protocol and are willing to
participate in the study and comply with all its procedures and restrictions. Informed consent must be obtained
from the patient and/or a designated representative prior to initiating screening procedures to evaluate their
eligibility for the study.~2. Aged 50 - 79 years inclusive.~3. Meet the diagnosis of probable AD consistent
with:~ * Revised National Institute on Aging-Alzheimer's Association (NIA-ADA) criteria and~ * Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) criteria.~4. Of mild to moderate severity: Mini-Mental Status
Exam (MMSE) score 10 - 24 inclusive.~5. Rosen-Modified Hachinski Ischemia Score of â‰¤4.~6. Have a suitable
caregiver to supervise the at-home administration of study drugs and observe for AEs.~7. Treated with donepezil
10 mg/day (given once daily) for at least 4 weeks just prior to study entry and to have safely tolerated, as
judged clinically by the investigator.~8. Patients must be in generally good health as indicated by their
medical history and physical examination, vital signs, electrocardiogram (ECG), and standard laboratory tests.~
